Published in Eur J Pharmacol on October 27, 1987
(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys. J Neurol Neurosurg Psychiatry (1990) 0.75
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology (2005) 1.75
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience (1989) 1.64
Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord (1991) 1.62
Source localisation of 62-electrode human laser pain evoked potential data using a realistic head model. Int J Psychophysiol (2001) 1.39
Problems associated with iontophoretic studies in the caudate nucleus and substantia nigra. Neuropharmacology (1974) 1.37
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain (1984) 1.14
Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia (1993) 1.12
Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience (1987) 1.04
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 1.03
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol (2000) 1.00
Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine. J Pharm Pharmacol (1974) 0.99
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol (1998) 0.98
Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat. Neuroscience (1983) 0.96
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol (1999) 0.95
Effects of manipulating pallidal and nigral GABA on striatally-mediated head-turning in the rat [proceedings]. Br J Pharmacol (1977) 0.95
The effect of bicuculline on the gamma-aminobutyric acid (GABA) receptors of neurons of Periplaneta americana and Helix aspersa. Brain Res (1971) 0.93
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord (1991) 0.92
Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neurosci Lett (1984) 0.90
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord (2001) 0.90
Proceedings: Pharmacological studies on single neurones in the substantia nigra of the rat. Br J Pharmacol (1974) 0.89
Nucleus tegmenti pedunculopontinus: efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase. Neuroscience (1983) 0.89
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord (1999) 0.88
Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat. Eur J Neurosci (1994) 0.88
Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology (1985) 0.87
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol (1994) 0.87
Basal ganglia and other afferent projections to the peribrachial region in the rat: a study using retrograde and anterograde transport of horseradish peroxidase. Neuroscience (1981) 0.87
The effect of morphine on turning behaviour in rats and mice with unilateral 6-hydroxydopamine lesions [proceedings]. Br J Pharmacol (1976) 0.87
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol (2001) 0.86
Induction of chorea and dystonia in parkinsonian primates. Mov Disord (1990) 0.86
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res (1993) 0.86
Picrotoxin antagonism of gamma-aminobutyric acid inhibitory responses and synaptic inhibition in the rat substantia nigra. Br J Pharmacol (1973) 0.86
Anatomic localization of dyskinesia in children with "profound" perinatal hypoxic-ischemic injury. AJNR Am J Neuroradiol (2009) 0.86
Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res (1989) 0.85
The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain (1989) 0.85
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol (1997) 0.85
A method for investigating neurotransmission in the basal ganglia using combined stimulation and intracerebral drug injection [proceedings]. Br J Pharmacol (1977) 0.85
Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. Br J Neurosurg (1992) 0.85
Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J (2001) 0.85
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res (1990) 0.84
Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci Lett (1985) 0.84
Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Res (1992) 0.84
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1989) 0.84
Further evidence for the stimulation of rat brain dopamine receptors by ergometrine. J Pharm Pharmacol (1974) 0.84
Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey. Neurosci Lett (1984) 0.84
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol (2001) 0.84
Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Lett (1986) 0.84
[3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Mov Disord (1998) 0.83
A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett (1994) 0.83
Subthalamic nucleus efferent projection to the cerebral cortex. Neuroscience (1981) 0.83
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord (1990) 0.82
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Exp Neurol (1996) 0.82
Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat. Brain Res (1994) 0.82
The efferent projections of the nucleus accumbens in the rat. Brain Res (1977) 0.82
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol (1996) 0.82
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol (2001) 0.81
Experimental torticollis in the monkey produced by unilateral 6-hydroxy-dopamine brain lesions. Brain Res (1978) 0.81
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res (1995) 0.80
Experimental hemiballismus in the baboon produced by injection of a gamma-aminobutyric acid antagonist into the basal ganglia. Neurosci Lett (1980) 0.80
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord (2005) 0.80
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1987) 0.80
Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Adv Neurol (1998) 0.80
The organisation of the efferent projections of the zona incerta. J Anat (1985) 0.80
Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp Neurol (1998) 0.79
Subthalamic projection to nucleus tegmenti pedunculopontinus in the rat. Neurosci Lett (1981) 0.79
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. Brain Res (1990) 0.79
Modeling the functional organization of the basal ganglia. A parallel distributed processing approach. Mov Disord (1991) 0.79
Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Neurosci Lett (1991) 0.79
Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res (1985) 0.78
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiol Dis (2001) 0.78
Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. J Neurol Sci (1990) 0.78
Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey. Mov Disord (1992) 0.78
Acute and chronic behavioural sequelae resulting from intrastriatal injection of an NMDA agonist. Pharmacol Biochem Behav (1994) 0.78
Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway. Exp Neurol (1979) 0.77
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Adv Neurol (1998) 0.77
A semi-quantitative atlas of 5-hydroxytryptamine-1 receptors in the primate brain. Neuroscience (1986) 0.77
Extracellular amino acid levels in the globus pallidus of the conscious primate studied by intracerebral microdialysis. Br J Pharmacol (1989) 0.77
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol (2004) 0.77
Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res (1988) 0.77
Timing of levodopa therapy: evidence from MPTP-treated primates. Lancet (1987) 0.76
Potential nondopaminergic drugs for Parkinson's disease. Adv Neurol (2003) 0.76
Autoradiography of transferrin receptors in the human brain. Neurosci Lett (1996) 0.76
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Mov Disord (1998) 0.76
Effects of benzodiazepines and barbiturates in a GABA-dependent animal model: interactions with muscimol in the globus pallidus [proceedings]. Br J Pharmacol (1979) 0.75
Motor manifestations and basal ganglia output activity: the paradox continues. Mov Disord (2013) 0.75
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. Neuroscience (1993) 0.75
Effects of intrapallidal administration of convulsant drugs on head-turning evoked by striatal stimulation in rats [proceedings]. Br J Pharmacol (1978) 0.75
The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions. Brain Res (1978) 0.75
Apparatus for measuring limb tonicity in the rat: application to the study of morphine-induced rigidity [proceedings]. J Physiol (1980) 0.75